Can methotrexate be taken concurrently with ibuprofen?

Can Methotrexate and Ibuprofen Be Taken Together?

Methotrexate and ibuprofen can be used together for low-dose methotrexate therapy (≤25 mg weekly) in rheumatoid arthritis and psoriasis, but this combination requires caution and close monitoring, particularly in patients with risk factors for toxicity.

Key Considerations

The FDA drug label explicitly warns against concurrent use of NSAIDs with high-dose methotrexate (such as in osteosarcoma treatment), stating that "nonsteroidal anti-inflammatory drugs should not be administered prior to or concomitantly with the high doses of methotrexate" 1. However, the situation differs substantially for low-dose methotrexate used in inflammatory conditions.

Evidence for Low-Dose Methotrexate (≤25 mg weekly)

For rheumatoid arthritis and psoriasis patients: The British Association of Dermatologists guidelines acknowledge that while case reports document significant morbidity and mortality with certain NSAIDs (particularly naproxen, diclofenac, ibuprofen, and indomethacin), these cases often involved additional interacting medications 2. Importantly, one study found no increased toxicity in patients on both low-dose methotrexate and naproxen.

The most recent and highest-quality evidence comes from a 2018 Danish register-based cohort study of over 21,000 episodes, which found that concomitant use of low-dose methotrexate and NSAIDs was associated with a significantly increased risk of serious adverse events (weighted hazard ratio 1.40; 95% CI, 1.07-1.82), specifically acute renal failure and cytopenia 3. This represents the strongest evidence against routine combination use.

However, a 2025 expert review concluded that NSAIDs have minimal impact on methotrexate pharmacokinetics and that short-term NSAID use (≤14 days) is unlikely to substantially increase adverse event risk in patients without risk factors 4.

Clinical Algorithm for Decision-Making

When Combination Use May Be Acceptable:

• Low-dose methotrexate (7.5-20 mg weekly)
• Short-term NSAID use (≤14 days for acute pain)
• Absence of risk factors (see below)
• Adequate monitoring in place

High-Risk Situations Requiring Avoidance or Extreme Caution:

1. Renal insufficiency - NSAIDs reduce renal elimination of methotrexate 2, 1
2. Methotrexate dose >20 mg/week 4
3. Elderly patients - often have decreased renal function 1
4. Dehydration 4
5. Concurrent use of other interacting drugs (trimethoprim, allopurinol) 2
6. Diabetes mellitus 4
7. Concurrent aspirin in analgesic doses 4

Monitoring Requirements When Used Together:

• Baseline: Complete blood count with differential, renal function tests, liver function tests 2
• During concurrent use:
  • Repeat CBC and renal function within 2-4 weeks of starting NSAID
  • Monitor for signs of toxicity: mouth sores, unusual bleeding, severe fatigue, persistent cough
  • More frequent monitoring if any risk factors present

Important Caveats

Avoid taking NSAIDs on the same day as methotrexate. One study demonstrated transient thrombocytopenia specifically when NSAIDs were taken on the same weekday as methotrexate 5.

The FDA label explicitly states: "Caution should be used when NSAIDs and salicylates are administered concomitantly with lower doses of methotrexate" and notes that "larger doses could lead to unexpected toxicity" 1.

For high-dose methotrexate (chemotherapy doses): The combination is contraindicated due to deaths from severe hematologic and gastrointestinal toxicity 1.

Practical Recommendation

For patients on low-dose methotrexate who need pain relief:

• First-line: Acetaminophen/paracetamol (though no studies were identified, it lacks the renal interaction mechanism)
• If NSAID needed: Use the lowest effective dose for the shortest duration (≤14 days)
• Avoid ibuprofen if: Any of the high-risk factors listed above are present
• Never use: Anti-inflammatory doses of aspirin with methotrexate 5
• Timing: Do not take ibuprofen on the same day as the weekly methotrexate dose

The evidence suggests this combination increases risk by approximately 40% 3, which must be weighed against the clinical need for NSAID therapy in each individual case.